Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: A retrospective analysis

The Lancet Infectious Diseases

Volumn 15, Issue 7, 2015, Pages 803-809

  Payne, Helen ^a   Mkhize, Nonhlanhla ^c   Otwombe, Kennedy ^d   Lewis, Joanna ^b   Panchia, Ravindre ^d   Callard, Robin ^a,b   Morris, Lynn ^c   Babiker, Abdel ^e   Violari, Avy ^d   Cotton, Mark F ^f   Klein, Nigel J ^a   Gibb, Diana M ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

^f STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AGE; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV RAPID TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SERODIAGNOSIS; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECTS; HIV SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR;

AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HIV-2; HUMANS; IMMUNOCHROMATOGRAPHY; INFANT; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; VIRAL LOAD;

EID: 84937519381     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00087-0     Document Type: Article

References (28)

1. Palasanthiran P, Robertson P, Ziegler JB, Graham GG Decay of transplacental human immunodeficiency virus type 1 antibodies in neonates and infants. J Infect Dis 1994, 170:1593-1596.
2. The European Collaborative Study. Pediatr Infect Dis J 1997, 16:1151-1156. Hospitalization of children born to human immunodeficiency virus-infected women in Europe.
3. Hainaut M, Peltier CA, Goetghebuer T, et al. Seroreversion in children infected with HIV type 1 who are treated in the first months of life is not a rare event. Clin Infect Dis 2005, 41:1820-1821.
4. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000, 74:6984-6991.
5. Viganò A, Trabattoni D, Schneider L, et al. Failure to eradicate HIV despite fully successful HAART initiated in the first days of life. J Pediatr 2006, 148:389-391.
6. Zanchetta M, Anselmi A, Vendrame D, et al. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antiviral Ther 2008, 13:47-55.
7. Butler KM, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. Pediatr Infect Dis J 2015, 34:e48-e51.
8. Hare CB, Pappalardo BL, Busch MP, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006, 42:700-708.
9. O'Sullivan CE, Peng R, Cole KS, et al. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART. J Med Virol 2002, 67:320-326.
10. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach 2013, WHO, WHO Press, Geneva.
11. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008, 82:12449-12463.
12. Overbaugh J, Morris L The antibody response against HIV-1. Cold Spring Harb Perspect Med 2012, 2:a007039.
13. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008, 105:7552-7557.
14. Huang KH, Bonsall D, Katzourakis A, et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun 2010, 1:102.
15. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359:11.
16. Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the Children with HIV Early Antiretroviral (CHER) randomised trial. Lancet 2013, 382:1555-1563.
17. Gray ES, Madiga MC, Hermanus T, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011, 85:4828-4840.
18. Li Y, Svehla K, Louder MK, et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009, 83:1045-1059.
19. Riley KF, Hobson MP, Bence SJ Mathematical methods for physics and engineering 2003, Cambridge University Press, Cambridge. 2nd edn.
20. A language and environment for statistical computing 2011, R Development Core Team, R Foundation for Statistical Computing, Vienna.
21. Payne H, Watters S, Callard R, et al. Early ART and sustained virological suppression limits HIV proviral DNA reservoir: CHER evidence. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23-26, 2015. Abstr 35.
22. Lilian RR, Kalk E, Bhowan K, et al. Early diagnosis of in utero and intrapartum HIV infection in infants prior to 6 weeks of age. J Clin Microbiol 2012, 50:2373-2377.
23. Grundmann N, Iliff P, Stringer J, Wilfert C Presumptive diagnosis of severe HIV infection to determine the need for antiretroviral therapy in children less than 18 months of age. Bull World Health Organ 2011, 89:513-520.
24. Geretti AM, Fox Z, Johnson JA, et al. Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. PLoS One 2013, 8:e69266.
25. Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis 2014, 210:1529-1538.
26. Claassen M, van Zyl GU, Korsman SN, Smit L, Cotton MF, Preiser W Pitfalls with rapid HIV antibody testing in HIV-infected children in the Western Cape, South Africa. J Clin Virol 2006, 37:68-71.
27. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog 2013, 9:e1003211.
28. Burbelo PD, Bayat A, Rhodes CS, et al. HIV antibody characterization as a method to quantify reservoir size during curative interventions. J Infect Dis 2014, 209:1613-1617.